New tools for the quantitative assessment of prodrug delivery and neurotoxicity

Lynn E. Samuelson, Randy L. Scherer, Michael Vansaun, Kang Hsien Fan, E. Ashley Dozier, Kathy J. Carter, Tatsuki Koyama, Yu Shyr, Michael Aschner, Gregg D. Stanwood, Darryl J. Bornhop, Lynn M. Matrisian, J. Oliver McIntyre

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Systemic off-target toxicities, including neurotoxicity, are prevalent side effects in cancer patients treated with a number of otherwise highly efficacious anticancer drugs. In the current study, we have: (1) developed a new analytical metric for the in vivo preclinical assessment of systemic toxicities/neurotoxicity of new drugs and delivery systems; and (2) evaluated, in mice, the in vivo efficacy and toxicity of a versatile and modular NanoDendron (ND) drug delivery and imaging platform that we recently developed. Our paclitaxel-carrying ND prodrug, NDPXL, is activated following proteolytic cleavage by MMP9, resulting in localized cytotoxic chemotherapy. Using click chemistry, we combined NDPXL with a traceable beacon, NDPB, yielding NDPXL-NDPB that functions as a theranostic compound. In vivo fluorescence FRET imaging of this theranostic platform was used to confirm localized delivery to tumors and to assess the efficiency of drug delivery to tumors, achieving 25-30% activation in the tumors of an immunocompetent mouse model of breast cancer. In this model, ND-drug exhibited anti-tumor efficacy comparable to nab-paclitaxel, a clinical formulation. In addition, we combined neurobehavioral metrics of nociception and sensorimotor performance of individual mice to develop a novel composite toxicity score that reveals and quantifies peripheral neurotoxicity, a debilitating long-term systemic toxicity of paclitaxel therapy. Importantly, mice treated with nab-paclitaxel developed changes in behavioral metrics with significantly higher toxicity scores indicative of peripheral neuropathy, while mice treated with NDPXL showed no significant changes in behavioral responses or toxicity score. Our ND formulation was designed to be readily adaptable to incorporate different drugs, imaging modalities and/or targeting motifs. This formulation has significant potential for preclinical and clinical tools across multiple disease states. The studies presented here report a novel toxicity score for assessing peripheral neuropathy and demonstrate that our targeted, theranostic NDs are safe and effective, providing localized tumor delivery of a chemotherapeutic and with reduced common neurotoxic side-effects.

Original languageEnglish (US)
Pages (from-to)88-98
Number of pages11
JournalNeuroToxicology
Volume47
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Prodrugs
Toxicity
Tumors
Neoplasms
Pharmaceutical Preparations
Peripheral Nervous System Diseases
Paclitaxel
Drug delivery
Imaging techniques
Click Chemistry
Nociception
Optical Imaging
Drug Delivery Systems
Chemotherapy
Breast Neoplasms
Drug Therapy
Fluorescence
Chemical activation
Theranostic Nanomedicine
Composite materials

Keywords

  • Neuropathy
  • Protease-mediated drug delivery
  • Protease-mediated imaging
  • Theranostic paclitaxel
  • Toxicity assessment

ASJC Scopus subject areas

  • Neuroscience(all)
  • Toxicology

Cite this

Samuelson, L. E., Scherer, R. L., Vansaun, M., Fan, K. H., Dozier, E. A., Carter, K. J., ... McIntyre, J. O. (2015). New tools for the quantitative assessment of prodrug delivery and neurotoxicity. NeuroToxicology, 47, 88-98. https://doi.org/10.1016/j.neuro.2015.02.005

New tools for the quantitative assessment of prodrug delivery and neurotoxicity. / Samuelson, Lynn E.; Scherer, Randy L.; Vansaun, Michael; Fan, Kang Hsien; Dozier, E. Ashley; Carter, Kathy J.; Koyama, Tatsuki; Shyr, Yu; Aschner, Michael; Stanwood, Gregg D.; Bornhop, Darryl J.; Matrisian, Lynn M.; McIntyre, J. Oliver.

In: NeuroToxicology, Vol. 47, 01.03.2015, p. 88-98.

Research output: Contribution to journalArticle

Samuelson, LE, Scherer, RL, Vansaun, M, Fan, KH, Dozier, EA, Carter, KJ, Koyama, T, Shyr, Y, Aschner, M, Stanwood, GD, Bornhop, DJ, Matrisian, LM & McIntyre, JO 2015, 'New tools for the quantitative assessment of prodrug delivery and neurotoxicity', NeuroToxicology, vol. 47, pp. 88-98. https://doi.org/10.1016/j.neuro.2015.02.005
Samuelson, Lynn E. ; Scherer, Randy L. ; Vansaun, Michael ; Fan, Kang Hsien ; Dozier, E. Ashley ; Carter, Kathy J. ; Koyama, Tatsuki ; Shyr, Yu ; Aschner, Michael ; Stanwood, Gregg D. ; Bornhop, Darryl J. ; Matrisian, Lynn M. ; McIntyre, J. Oliver. / New tools for the quantitative assessment of prodrug delivery and neurotoxicity. In: NeuroToxicology. 2015 ; Vol. 47. pp. 88-98.
@article{1153e99cb59c4e54a330b8433aeb8f00,
title = "New tools for the quantitative assessment of prodrug delivery and neurotoxicity",
abstract = "Systemic off-target toxicities, including neurotoxicity, are prevalent side effects in cancer patients treated with a number of otherwise highly efficacious anticancer drugs. In the current study, we have: (1) developed a new analytical metric for the in vivo preclinical assessment of systemic toxicities/neurotoxicity of new drugs and delivery systems; and (2) evaluated, in mice, the in vivo efficacy and toxicity of a versatile and modular NanoDendron (ND) drug delivery and imaging platform that we recently developed. Our paclitaxel-carrying ND prodrug, NDPXL, is activated following proteolytic cleavage by MMP9, resulting in localized cytotoxic chemotherapy. Using click chemistry, we combined NDPXL with a traceable beacon, NDPB, yielding NDPXL-NDPB that functions as a theranostic compound. In vivo fluorescence FRET imaging of this theranostic platform was used to confirm localized delivery to tumors and to assess the efficiency of drug delivery to tumors, achieving 25-30{\%} activation in the tumors of an immunocompetent mouse model of breast cancer. In this model, ND-drug exhibited anti-tumor efficacy comparable to nab-paclitaxel, a clinical formulation. In addition, we combined neurobehavioral metrics of nociception and sensorimotor performance of individual mice to develop a novel composite toxicity score that reveals and quantifies peripheral neurotoxicity, a debilitating long-term systemic toxicity of paclitaxel therapy. Importantly, mice treated with nab-paclitaxel developed changes in behavioral metrics with significantly higher toxicity scores indicative of peripheral neuropathy, while mice treated with NDPXL showed no significant changes in behavioral responses or toxicity score. Our ND formulation was designed to be readily adaptable to incorporate different drugs, imaging modalities and/or targeting motifs. This formulation has significant potential for preclinical and clinical tools across multiple disease states. The studies presented here report a novel toxicity score for assessing peripheral neuropathy and demonstrate that our targeted, theranostic NDs are safe and effective, providing localized tumor delivery of a chemotherapeutic and with reduced common neurotoxic side-effects.",
keywords = "Neuropathy, Protease-mediated drug delivery, Protease-mediated imaging, Theranostic paclitaxel, Toxicity assessment",
author = "Samuelson, {Lynn E.} and Scherer, {Randy L.} and Michael Vansaun and Fan, {Kang Hsien} and Dozier, {E. Ashley} and Carter, {Kathy J.} and Tatsuki Koyama and Yu Shyr and Michael Aschner and Stanwood, {Gregg D.} and Bornhop, {Darryl J.} and Matrisian, {Lynn M.} and McIntyre, {J. Oliver}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.neuro.2015.02.005",
language = "English (US)",
volume = "47",
pages = "88--98",
journal = "NeuroToxicology",
issn = "0161-813X",
publisher = "Elsevier",

}

TY - JOUR

T1 - New tools for the quantitative assessment of prodrug delivery and neurotoxicity

AU - Samuelson, Lynn E.

AU - Scherer, Randy L.

AU - Vansaun, Michael

AU - Fan, Kang Hsien

AU - Dozier, E. Ashley

AU - Carter, Kathy J.

AU - Koyama, Tatsuki

AU - Shyr, Yu

AU - Aschner, Michael

AU - Stanwood, Gregg D.

AU - Bornhop, Darryl J.

AU - Matrisian, Lynn M.

AU - McIntyre, J. Oliver

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Systemic off-target toxicities, including neurotoxicity, are prevalent side effects in cancer patients treated with a number of otherwise highly efficacious anticancer drugs. In the current study, we have: (1) developed a new analytical metric for the in vivo preclinical assessment of systemic toxicities/neurotoxicity of new drugs and delivery systems; and (2) evaluated, in mice, the in vivo efficacy and toxicity of a versatile and modular NanoDendron (ND) drug delivery and imaging platform that we recently developed. Our paclitaxel-carrying ND prodrug, NDPXL, is activated following proteolytic cleavage by MMP9, resulting in localized cytotoxic chemotherapy. Using click chemistry, we combined NDPXL with a traceable beacon, NDPB, yielding NDPXL-NDPB that functions as a theranostic compound. In vivo fluorescence FRET imaging of this theranostic platform was used to confirm localized delivery to tumors and to assess the efficiency of drug delivery to tumors, achieving 25-30% activation in the tumors of an immunocompetent mouse model of breast cancer. In this model, ND-drug exhibited anti-tumor efficacy comparable to nab-paclitaxel, a clinical formulation. In addition, we combined neurobehavioral metrics of nociception and sensorimotor performance of individual mice to develop a novel composite toxicity score that reveals and quantifies peripheral neurotoxicity, a debilitating long-term systemic toxicity of paclitaxel therapy. Importantly, mice treated with nab-paclitaxel developed changes in behavioral metrics with significantly higher toxicity scores indicative of peripheral neuropathy, while mice treated with NDPXL showed no significant changes in behavioral responses or toxicity score. Our ND formulation was designed to be readily adaptable to incorporate different drugs, imaging modalities and/or targeting motifs. This formulation has significant potential for preclinical and clinical tools across multiple disease states. The studies presented here report a novel toxicity score for assessing peripheral neuropathy and demonstrate that our targeted, theranostic NDs are safe and effective, providing localized tumor delivery of a chemotherapeutic and with reduced common neurotoxic side-effects.

AB - Systemic off-target toxicities, including neurotoxicity, are prevalent side effects in cancer patients treated with a number of otherwise highly efficacious anticancer drugs. In the current study, we have: (1) developed a new analytical metric for the in vivo preclinical assessment of systemic toxicities/neurotoxicity of new drugs and delivery systems; and (2) evaluated, in mice, the in vivo efficacy and toxicity of a versatile and modular NanoDendron (ND) drug delivery and imaging platform that we recently developed. Our paclitaxel-carrying ND prodrug, NDPXL, is activated following proteolytic cleavage by MMP9, resulting in localized cytotoxic chemotherapy. Using click chemistry, we combined NDPXL with a traceable beacon, NDPB, yielding NDPXL-NDPB that functions as a theranostic compound. In vivo fluorescence FRET imaging of this theranostic platform was used to confirm localized delivery to tumors and to assess the efficiency of drug delivery to tumors, achieving 25-30% activation in the tumors of an immunocompetent mouse model of breast cancer. In this model, ND-drug exhibited anti-tumor efficacy comparable to nab-paclitaxel, a clinical formulation. In addition, we combined neurobehavioral metrics of nociception and sensorimotor performance of individual mice to develop a novel composite toxicity score that reveals and quantifies peripheral neurotoxicity, a debilitating long-term systemic toxicity of paclitaxel therapy. Importantly, mice treated with nab-paclitaxel developed changes in behavioral metrics with significantly higher toxicity scores indicative of peripheral neuropathy, while mice treated with NDPXL showed no significant changes in behavioral responses or toxicity score. Our ND formulation was designed to be readily adaptable to incorporate different drugs, imaging modalities and/or targeting motifs. This formulation has significant potential for preclinical and clinical tools across multiple disease states. The studies presented here report a novel toxicity score for assessing peripheral neuropathy and demonstrate that our targeted, theranostic NDs are safe and effective, providing localized tumor delivery of a chemotherapeutic and with reduced common neurotoxic side-effects.

KW - Neuropathy

KW - Protease-mediated drug delivery

KW - Protease-mediated imaging

KW - Theranostic paclitaxel

KW - Toxicity assessment

UR - http://www.scopus.com/inward/record.url?scp=84924625852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924625852&partnerID=8YFLogxK

U2 - 10.1016/j.neuro.2015.02.005

DO - 10.1016/j.neuro.2015.02.005

M3 - Article

C2 - 25732874

AN - SCOPUS:84924625852

VL - 47

SP - 88

EP - 98

JO - NeuroToxicology

JF - NeuroToxicology

SN - 0161-813X

ER -